General Information of Drug (ID: DM6NX4H)

Drug Name
PKI-402 Drug Info
Synonyms
PKI-402; 1173204-81-3; PKI402; PKI 402; CHEMBL589258; 1-(4-(3-ethyl-7-morpholino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-3-(4-(4-methylpiperazine-1-carbonyl)phenyl)urea; 1-[4-[3-Ethyl-7-(morpholin-4-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl]-3-[4-[(4-methylpiperazin-1-yl)carbonyl]phenyl]urea; J-504117; ZAXFYGBKZSQBIV-UHFFFAOYSA-N; MLS006010978; SCHEMBL3401810; DTXSID30657809; EX-A040; MolPort-022-902-305; BCP02609; C29H34N10O3; s2739; BDBM50308767; ZINC49745945; ABP000110; AKOS022526182; QC-7256; RL00651
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
PubChem CID
44187953
CAS Number
CAS 1173204-81-3
TTD Drug ID
DM6NX4H

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
PI3-kinase gamma (PIK3CG) DTT PIK3CG 1.98E-01 -0.05 -0.55
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: di... J Med Chem. 2010 Jan 28;53(2):798-810.